April 2021 updates to the website
08 April 2021
The website has now been updated following April's LSCMMG
The following Items have been updated and added to the website and will be ratified following the next Joint Committee of CCGs (JCCCG) Meeting:
Erenumab - For preventing migraine (TA682)
Baricitinib - For treating moderate to severe atopic dermatitis (TA681)